Ratings by BTIG (Thomas Shrader)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/21/2026 | Invivyd Inc. | IVVD | Maintain | Buy (N/A) |
|
Details | ||
| 1/20/2026 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
2.10 (4.89) |
132.86% | Details | |
| 1/7/2026 | Bright Minds Biosciences Inc. | DRUG | Maintain | Buy (N/A) |
|
Details | ||
| 12/22/2025 | Invivyd Inc. | IVVD | New Coverage | Buy (N/A) |
2.30 (1.80) |
-21.74% | Details | |
| 11/17/2025 | Alto Neuroscience | ANRO | New Coverage | Buy (N/A) |
12.11 (20.76) |
71.43% | Details | |
| 10/13/2025 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 9/8/2025 | Bright Minds Biosciences Inc. | DRUG | New Coverage | Buy (N/A) |
42.24 (76.87) |
81.98% | Details | |
| 8/25/2025 | Gain Therapeutics | GANX | Maintain | Buy (N/A) |
|
Details | ||
| 8/19/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2025 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | Harrow Health | HROW | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Verona Pharma | VRNA | Downgrade | Neutral (Buy) |
86.86 (106.91) |
23.08% | Details | |
| 7/1/2025 | INmune Bio Inc. | INMB | Downgrade | Neutral (Buy) |
5.33 (1.33) |
-75.05% | Details | |
| 6/18/2025 | Aldeyra Therapeutics | ALDX | Maintain | Buy (N/A) |
|
Details | ||
| 6/12/2025 | Harrow Health | HROW | New Coverage | Buy (N/A) |
31.17 (36.35) |
16.62% | Details | |
| 4/22/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/7/2025 | Aldeyra Therapeutics | ALDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2025 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 3/24/2025 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2025 | Aldeyra Therapeutics | ALDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2025 | Novavax | NVAX | New Coverage | Buy (N/A) |
7.32 (9.98) |
36.34% | Details | |
| 2/18/2025 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2025 | Arcturus Therapeutics | ARCT | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2025 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2025 | Arcturus Therapeutics | ARCT | New Coverage | Buy (N/A) |
16.49 (7.11) |
-56.88% | Details | |
| 1/7/2025 | Verona Pharma | VRNA | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2024 | Aldeyra Therapeutics | ALDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2024 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2024 | Gain Therapeutics | GANX | Maintain | Buy (N/A) |
|
Details | ||
| 9/23/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2024 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2024 | Athira Pharma | ATHA | Downgrade | Neutral (Buy) |
3.09 (6.75) |
118.45% | Details | |
| 9/3/2024 | Gain Therapeutics | GANX | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 6/18/2024 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 5/31/2024 | AC Immune SA | ACIU | New Coverage | Buy (N/A) |
3.67 (2.79) |
-23.98% | Details | |
| 5/20/2024 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 4/23/2024 | Verona Pharma | VRNA | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2024 | Pliant Therapeutics | PLRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/9/2024 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2023 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
3.54 (1.91) |
-46.05% | Details | |
| 11/20/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2023 | Silence Therapeutics | SLN | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2023 | ProMIS Neurosciences | PMN | New Coverage | Buy (N/A) |
1.98 (23.40) |
1081.82% | Details | |
| 6/30/2023 | Sigilon Therapeutics | SGTX | Downgrade | Neutral (Buy) |
3.93 (22.47) |
471.76% | Details | |
| 6/6/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2023 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2023 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2022 | Verona Pharma | VRNA | Maintain | Buy (N/A) |
|
Details | ||
| 12/7/2022 | SQZ Biotechnologies | SQZ | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2022 | Minerva Neurosciences | NERV | Maintain | Buy (N/A) |
|
Details | ||
| 10/6/2022 | SQZ Biotechnologies | SQZ | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2022 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2022 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2022 | Sigilon Therapeutics | SGTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2021 | Sigilon Therapeutics | SGTX | New Coverage | Buy (N/A) |
4.99 (22.47) |
350.3% | Details | |
| 10/29/2021 | Sigilon Therapeutics | SGTX | New Coverage | Buy (N/A) |
5.54 (22.47) |
305.6% | Details | |
| 7/29/2021 | MEI Pharma | MEIP | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2021 | MacroGenics | MGNX | New Coverage | Buy (N/A) |
20.49 (2.23) |
-89.12% | Details | |
| 5/5/2021 | Esperion Therapeutics | ESPR | Maintain | Buy (N/A) |
|
Details | ||
| 4/12/2021 | Gain Therapeutics | GANX | New Coverage | Buy (N/A) |
13.98 (3.05) |
-78.18% | Details | |
| 3/26/2021 | GX Acquisition Corp. | GXGX | New Coverage | Buy (N/A) |
10.06 (10.20) |
1.39% | Details | |
| 3/15/2021 | Nuvation Bio Inc | NUVB | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2021 | Voyager Therapeutics | VYGR | Downgrade | Neutral (Buy) |
8.00 (3.90) |
-51.25% | Details | |
| 1/29/2021 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 1/21/2021 | Gritstone Oncology | GRTS | Maintain | Buy (N/A) |
|
Details | ||
| 12/14/2020 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 11/24/2020 | SQZ Biotechnologies | SQZ | New Coverage | Buy (N/A) |
27.62 (0.44) |
-98.41% | Details | |
| 11/18/2020 | Silence Therapeutics | SLN | New Coverage | Buy (N/A) |
16.70 (6.23) |
-62.69% | Details | |
| 11/18/2020 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Buy) |
81.21 (122.21) |
50.49% | Details | |
| 11/11/2020 | Voyager Therapeutics | VYGR | Maintain | Neutral (N/A) |
|
Details | ||
| 10/16/2020 | Denali Therapeutics Inc. | DNLI | Downgrade | Neutral (Buy) |
43.51 (19.69) |
-54.75% | Details | |
| 9/1/2020 | Checkmate Pharmaceuticals | CMPI | New Coverage | Buy (N/A) |
15.58 (10.50) |
-32.61% | Details | |
| 9/1/2020 | INmune Bio Inc. | INMB | New Coverage | Buy (N/A) |
10.50 (5.33) |
-49.24% | Details | |
| 8/31/2020 | Cue Biopharma | CUE | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2020 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2020 | Cue Biopharma | CUE | Maintain | Buy (N/A) |
|
Details | ||
| 5/19/2020 | BridgeBio Pharma | BBIO | New Coverage | Buy (N/A) |
34.82 (65.36) |
87.71% | Details | |
| 5/14/2020 | Minerva Neurosciences | NERV | New Coverage | Buy (N/A) |
12.31 (6.01) |
-51.18% | Details | |
| 4/16/2020 | Arcus Biosciences | RCUS | Maintain | Buy (N/A) |
|
Details | ||
| 4/3/2020 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2020 | Esperion Therapeutics | ESPR | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2020 | Cue Biopharma | CUE | New Coverage | Buy (N/A) |
15.51 (0.30) |
-98.07% | Details | |
| 11/21/2019 | Alector Inc. | ALEC | New Coverage | Buy (N/A) |
15.80 (3.21) |
-79.68% | Details | |
| 10/15/2019 | Eidos Therapeutics | EIDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2019 | Sutro Biopharma | STRO | New Coverage | Buy (N/A) |
8.23 (25.29) |
207.29% | Details | |
| 9/24/2019 | NeuBase Therapeutics | NBSE | New Coverage | Buy (N/A) |
6.59 (0.38) |
-94.23% | Details | |
| 8/26/2019 | Seattle Genetics | SGEN | New Coverage | Neutral (N/A) |
76.29 (228.74) |
199.83% | Details | |
| 4/18/2019 | Verona Pharma | VRNA | New Coverage | Buy (N/A) |
6.12 (86.86) |
1319.28% | Details | |
| 4/18/2019 | Eidos Therapeutics | EIDX | New Coverage | Buy (N/A) |
25.01 (122.21) |
388.64% | Details | |
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Buy) |
320.59 (184.87) |
-42.33% | Details | |
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Buy) |
320.59 (320.59) |
0% | Details | |
| 3/18/2019 | Arcus Biosciences | RCUS | New Coverage | Buy (N/A) |
11.43 (31.38) |
174.54% | Details | |
| 3/18/2019 | Momenta Pharmaceuticals | MNTA | New Coverage | Neutral (N/A) |
14.00 (52.48) |
274.86% | Details | |
| 2/13/2019 | Synlogic Inc. | SYBX | New Coverage | Buy (N/A) |
8.91 (0.56) |
-93.71% | Details | |
| 2/13/2019 | MEI Pharma | MEIP | New Coverage | Buy (N/A) |
2.87 (3.07) |
6.97% | Details | |
| 2/13/2019 | Geron Corporation | GERN | New Coverage | Buy (N/A) |
1.29 (1.53) |
18.6% | Details | |
| 1/7/2019 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2018 | Biogen | BIIB | New Coverage | Buy (N/A) |
292.69 (320.59) |
9.53% | Details | |
| 12/21/2018 | Celgene | CELG | New Coverage | Neutral (N/A) |
65.58 (108.24) |
65.05% | Details | |
| 10/23/2018 | Gritstone Oncology | GRTS | New Coverage | Buy (N/A) |
15.01 (0.03) |
-99.8% | Details | |
| 10/16/2018 | Y-mAbs Therapeutics | YMAB | New Coverage | Buy (N/A) |
20.81 (8.61) |
-58.63% | Details | |
| 10/16/2018 | Esperion Therapeutics | ESPR | New Coverage | Buy (N/A) |
46.22 (2.73) |
-94.09% | Details | |
| 9/10/2018 | G1 Therapeutics | GTHX | New Coverage | Buy (N/A) |
60.85 (7.15) |
-88.25% | Details | |
| 9/10/2018 | Xencor, Inc. | XNCR | New Coverage | Buy (N/A) |
38.44 (11.32) |
-70.55% | Details | |
| 9/10/2018 | Voyager Therapeutics | VYGR | New Coverage | Buy (N/A) |
19.56 (3.90) |
-80.06% | Details | |
| 9/10/2018 | MacroGenics | MGNX | New Coverage | Buy (N/A) |
21.65 (2.23) |
-89.7% | Details |
